4.7 Review

Strength in numbers: antifungal strategies against fungal biofilms

Journal

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume 43, Issue 2, Pages 114-120

Publisher

ELSEVIER
DOI: 10.1016/j.ijantimicag.2013.10.023

Keywords

Candida; Biofilm; Antifungal; Echinocandin; Liposomal amphotericin B

Funding

  1. BBSRC
  2. Wellcome Trust
  3. GSK
  4. Gilead Sciences
  5. Technology Strategy Board
  6. Fulhold

Ask authors/readers for more resources

Pathogenic fungi have the capacity to form tenacious biofilm structures that are notoriously unresponsive to antifungal therapies. Fungal biofilms are ubiquitous, located all over the human host, including the oral cavity, respiratory tract, gastrointestinal tract, urinary tract, wounds and upon biomedical devices. This latter category represents one of the greatest hurdles in clinical management, where the presence of inert substrates such as a catheter provides a reservoir for fungal biofilm development. Here, Candida albicans is the most adept at forming biofilms and is the principal nosocomial fungal pathogen based on its high rates of mortality, which are often associated with the biofilm lifestyle. This review will summarise some of the key fungal biofilm-forming organisms and their clinical significance and will discuss current and novel strategies to manage these hard-to-treat infections based on in vitro and in vivo studies. (C) 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available